Ignite Creation Date:
2024-05-05 @ 10:16 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01074996
Status:
UNKNOWN
Last Update Posted:
2014-01-16
First Post:
2010-02-23
Brief Title:
Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers
Sponsor:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Organization:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Study Overview
Official Title:
A Randomized Open-label Multicenter Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers
Status:
UNKNOWN
Status Verified Date:
2014-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
APC-S1
Brief Summary:
A randomized open-label multicenter phase II study to compare the efficacy of S-1 and S-1 plus Leucovorin as second line treatment on gemcitabine-refractory patients with inoperable or advanced pancreatic cancersinvestigate the correlation between efficacy and the expressions of thymidylate synthase dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None